Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

Supportive Care in Cancer

Volumn 25, Issue 5, 2017, Pages 1673-1686

  Beckwée, David ^a   Leysen, Laurence ^a,b   Meuwis, Kaipo ^a   Adriaenssens, Nele ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b Pain in Motion Research Group   (Belgium)

Author keywords

Aromatase inhibitor; Arthralgia; Breast cancer; Prevalence

Indexed keywords

AROMATASE INHIBITOR; TAXANE DERIVATIVE;

ARTHRALGIA; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COCHRANE LIBRARY; DISEASE FREE SURVIVAL; HUMAN; INFORMATION RETRIEVAL; MEDLINE; MENOPAUSE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; WEB OF SCIENCE; BREAST NEOPLASMS; CHEMICALLY INDUCED; FEMALE; META ANALYSIS; PATHOLOGY; TREATMENT OUTCOME;

AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HUMANS; PREVALENCE; TREATMENT OUTCOME;

EID: 85012897631     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-017-3613-z     Document Type: Review

References (62)

1. Boyle P, LB; (2008) World Cancer Report 2008 World Health Organization, International agency for research on Cancer
2. Ferlay J SI, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
3. Stewart B, WC; (2014) World Cancer Report 2014
4. Wildiers H, Stordeur S, Vlayen J, Scholten R, Van de Wetering F, Bourgain C, Carly B, Christiaans M, Coquyt V, Lifrange E, Schobbens J-C, van Goethem M, Villeirs G, van Limbergen E, Neven P (2013) Breast cancer in women: diagnosis, treatment and follow-up. Belgian health care knowledge center
5. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S (2013) Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treat 140:233–240
6. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I, Locker GY, Tobias JS, Grp AT (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60–62
7. Coates AS, Keshaviah A, Thuerlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492
8. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE (2015) Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33:265–271
9. Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J (2010) Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123:9–24
10. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25:3877–3883
11. Dizdar O, Oezcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27:4955–4960
12. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639
13. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130:681–689
14. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adhere to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431–436
15. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
17. Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, Tangoku A, Sasa M (2011) The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436
18. Elmagarmid A FZ, Hammady H, Ilyas I, Khabsa M, Ouzzani M (2014) Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews Evidence-Informed Publich Health
19. Maunsell E GP, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol
20. Kaufman J (2011) Data extraction and assessment form—template
21. von Elm E AD, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2008) The strengthening the reporting of observational studies in epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol
22. Wallace D, Trikalinos, Lau, Trow, Schmid (2012) Closing the gap between methodologists and end-users: R as a computational back-end. Journal of statistical software
23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials Controlled clinical trials 7: 177–188
24. Higgins JPT GS (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011
25. Slavin RE (1995) Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 48:9–18
26. Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CH, van Laarhoven HW (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs 36:52–59
27. Horimoto Y, Saito M, Kasumi F (2009) Arthralgia in 329 patients taking aromatase inhibitors. Breast Care 4:319–323
28. Menas P, Merkel D, Hui W, Lawton J, Harper A, Carro G (2012) Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract 18:387–393
29. Moxley G (2010) Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clinical Breast Cancer 10:144–147
30. Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper E-M, Sperner-Unterweger B, Holzner B (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553–561
31. Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clinical breast cancer 7:775–778
32. Scarpa R, Atteno M, Peluso R, Costa L, Padula S, Di Minno MND, Caso F, Iervolino S, Vitiello M, Del Puente A (2011) Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. Jcr-Journal of Clinical Rheumatology 17:169–172
33. Thomas R, Williams M, Marshall C, Walker L (2008) Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. Br J Cancer 98:1494–1499
34. Yagata H, Ohtsu H, Komoike Y, Saji S, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K (2015) Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole Support Care Cancer
35. Egawa C, Hirokaga K, Takao S, Yamagami K, Miyashita M, Baba M, Ichii S, Konishi M, Kikawa Y, Minohata J, Okuno T, Miyauchi K, Wakita K, Suwa H, Hashimoto T, Nishino M, Matsumoto T, Hidaka T, Konishi Y, Sakoda Y, Miya A, Mitsunobu M, Nishikawa H, Kono S, Kokufu I, Sakita I, Kitatsuji K, Oh K, Miyoshi Y (2015) Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes International journal of clinical oncology
36. Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, Koenig K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Harbeck N (2014) COMPliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 25:372–377
37. Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E (2012) A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 131:277–285
38. Laroche F, Coste J, Medkour T, Cottu PH, Pierga J-Y, Lotz J-P, Beerblock K, Tournigand C, Decleves X, de Cremoux P, Bouhassira D, Perrott S (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. Journal of Pain 15:293–303
39. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. The Lancet Oncology 9:866–872
40. Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS (2013) Anastrozole-associated joint pain and other symptoms in patients with breast. cancer J Pain 14:290–296
41. Laroche M, Borg S, Lassoued S, De Lafontan B, Roche H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34:2259–2263
42. Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 64:1910–1918
43. Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24:1443–1449
44. Magliano (2010) Menopausal arthralgia: fact or fiction. Maturitas 67
45. Watt (2016) Hand osteoarthritis, menopause and menopausal hormone therapy. Maturitas 83
46. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31:115–123
47. Lefebvre C, Manheimer E, Glanville J (2011) Chapter 6: searching for studies. In: Higgins JPT, S G (eds) Cochrane handbook for systematic reviews of interventions version 510 (updated March 2011)
48. Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205
49. Nielsen RH, Christiansen C, Stolina M, Karsdal MA (2008) Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 152:21–27
50. Zhang Y, McAlindon TE, Hannan MT, Chaisson CE, Klein R, Wilson PW, Felson DT (1998) Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham study. Arthritis Rheum 41:1867–1873
51. Hart DJ, Doyle DV, Spector TD (1999) Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford study. Arthritis Rheum 42:17–24
52. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594–2598
53. Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens MR, Neven P (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104:87–91
54. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180:630–636
55. Vural P, Akgul C, Canbaz M (2006) Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res 54:298–302
56. Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL (2016) Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis Cancer Nurs
57. DeNysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’connor T (2014) Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. European journal of cancer care 23:493–501
58. Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33:1104–1111
59. Sahin S, Karatas F, Sever AR, Altundag K (2016) Current management of aromatase inhibitor-induced arthralgia. J buon 21:17–20
60. Nijs J, Torres-Cueco R, van Wilgen CP, Girbes EL, Struyf F, Roussel N, van Oosterwijck J, Daenen L, Kuppens K, Vanwerweeen L, Hermans L, Beckwee D, Voogt L, Clark J, Moloney N, Meeus M (2014) Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization pain. Pain physician 17:447–457
61. Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrandiz ME, Devoogdt N, Tassenoy A, Ickmans K, Goubert D, van Wilgen CP, Wijma AJ, Kuppens K, Hoelen W, Hoelen A, Moloney N, Meeus M (2016) Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta oncologica (Stockholm, Sweden) 55:659–663
62. Schiavon G, SI; (2014) Status of adjuvant endocrine therapy for breast cancer Breast Cancer Research